Adheris Health Limited · ASX:AHE
Adheris Health — Q3 FY26 Earnings Presentation
11 slides from Adheris Health's earnings presentation, Apr 29, 2026
Slide 1: Q3 FY26 Results Presentation
Q3 FY26 Results Presentation 29 April 2026 John Ciccio – CEO & Managing Director Sean Slattery – CFO/Executive Director 1 Q3 FY26 Results Presentation | © 2026 Adheris Health. All rights reserved.
Slide 2: Leader in pharmacy-led patient engagement solutions
Leader in pharmacy-led patient engagement solutions Overview Partnering with global pharma and U.S. based pharmacies to enable a personalised medication journey to help remove barriers of care Approach Plug and play solutions that help stakeholders improve patient experiences and outcomes • Strong r
Slide 3: Agenda
1. Q3 FY26 Financials 2. Technology Platform Update Agenda 3. Key Short-term Priorities 4. Investment Case 3 Q3 FY26 Results Presentation | © 2026 Adheris Health. All rights reserved.
Slide 4: Q3 FY26 Financial Results Summary
Q3 FY26 Financial Results Summary (AUD)* Operational momentum returning business to sustainable financial basis Cashflow Summary Revenue $6.1m $9.4m $5.4m $8.1m ($0.2m) ↓ $1.7m vs Q3 FY25 ($4.6m) Gross Profit Cash at Operating Investing FX $2.1m Cash at Q2 end Activities Activities Movement Q3 End ↓
Slide 5: Q3 Platform Update
Q3 Platform Update Several upgrades rolled out in Q3; substantial release planned for Q4 Q3 Upgrades • More precise program sizing and estimation Q4 Release Focus • UI / UX improvements to support staff • Increased digital program configurability • Setup and configuration of more complex program typ
Slide 6: Key Short-term Priorities
Key Short-term Priorities Build Scalable Diversify Revenue Sell Higher-margin Expand Pharmacy Enhance Digital Operation Solutions Network Engagement • Continue to optimise • Reduce dependence • Refocus our business • Increase the breadth • Level up our digital our cost base as we on vaccine revenue
Slide 7: Building a More Scalable Operation
Building a More Scalable Operation Substantial cost-out program and adoption of new technology for faster execution Labor Cost Normalisation • Lower labor run rate People Cost Comparison: FY25 vs Projected Annual Run Rate • Full benefits of cost-out program anticipated to be realised in Q4 FY26 $25.
Slide 8: Diversifying Revenue and Improving Mix
Diversifying Revenue and Improving Mix Non-Vaccine Revenue up 28 ppts YOY 100% 4% Sharpened commercial focus on growth and margin 6% 9% 90% 6% 10% 80% 17% 70% 34% • Continued shift from vaccine to non- 60% Non-Vaccine Revenue: vaccine revenue, helping to balance and 50% Showing Meaningful strengthen
Slide 9: Expanding Our Pharmacy Network with a Focus on Digital Connectivity
Expanding Our Pharmacy Network with a Focus on Digital Connectivity Rebuilding momentum with pharma and chain pharmacy partners DIGITAL REGULATORY PRODUCT GROWTH • Expanding presence in retail network with digital regulatory product • 2,064 stores are currently live +13.5m • 1,472 stores are in acti
Slide 10: Enhance Digital Engagement: Creating a Richer Patient Experience
Enhance Digital Engagement: Creating a Richer Patient Experience Upgraded digital engagement suite will provide next-gen personalisation at scale VASIT OR.com Mobile web Interactive Hello, Jen. Interactive TAKING experience Chat Voice EXP RES S MARKETS Rx: CONTROL WITH What can I JEN, we’re here to
Slide 11: Investment Case
Investment Case Undervalued, uniquely positioned for return to profitable growth in a large market Trusted Brand & Unique Solution for a Strategy Aligned to a Next-gen Platform Discipline and Focus Proven Leadership Large, High-Value Clear Path Back to Built to Scale on Path to Profits Market Growth